Trial Profile

An Observational Multi-cohort Study on the Use of Fosamprenavir-Ritonavir Among HIV-infected Children and Adolescents in Europe

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 30 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fosamprenavir (Primary) ; Ritonavir
Indications HIV-1 infections
Focus Adverse reactions
Acronyms PENTA Fosamprenavir
Sponsors ViiV Healthcare

Most Recent Events

08 Feb 2012 Company (ViiV Healthcare) added as trial sponsor and additional lead trial centre identified as reported by ClinicalTrials.gov.
03 Feb 2012 Additional location (United Kingdom) added and additional trial acronym (PENTA Fosamprenavir) identified as reported by ClinicalTrials.gov.
03 Feb 2012 Actual patient number (1) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com